Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Finished

microMESH Preclinical validation and market analysis of a microMESH implant for brain cancer eradication

Coordinator
Fondazione Istituto Italiano Di Tecnologia, Italy
Runs
1 July 2022 to 31 December 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069326

What the project is doing

In the project's own words, from its summary on CORDIS.

Despite tremendous progress in the treatment of several malignancies, glioblastoma continues to be the less curable form of any cancer with an overall average survival of 20 months from diagnosis. In this PoC, an interdisciplinary team of engineers, biotechnologists and technology-transfer experts will work to prove that a ground-breaking drug delivery implant – microMESH – can be engineered to deploy intracranially a chemo-immuno-combination therapy to eradicate glioblastoma and minimize its life-long complications. microMESH will be engineered to deliver chemotherapeutic drugs (taxanes) and monoclonal antibodies (anti-CD47), that normally would not cross the blood brain barrier, uniformly and deep in the tumor bed. microMESH will comprise two physically distinct compartments – a micrometric network of poly(lactic-co-glycolic acid) (PLGA) strands, carrying taxane molecules; a poly(vinyl alcohol) (PVA) microlayer, encapsulating anti-CD47.

Upon deposition on the tumor mass, the PVA microlayer will dissolve in a few days releasing directly on the tumor margins anti-CD47 while the thin and flexible PLGA network will progressively conform to the surrounding surface, establishing an intimate interaction with the malignant cells, and release taxanes in a sustained fashion over several weeks. While taxanes will prevent the rapid proliferating glioblastoma cells from growing, anti-CD47 will stimulate the removal of cancer cells by resident and infiltrating immune cells.

The success of this PoC will result in a preclinically validated microMESH for the treatment of newly diagnosed and recurrent glioblastoma. Upon subsequent completion of GLP toxicological and cGMP manufacturing studies, microMESH will advance to a Phase 1/2 trial expected to start as early as 2024. In this space, companies with validated Phase 1/2 assets have market capitals ranging from 50M to 400M€. A successful microMESH could lead to revenues of 10M €/year starting already in 2027.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Istituto Italiano Di TecnologiaGenovaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI